Sanofi-Aventis and AEterna Zentaris sign development agreement for BPH drug

Mon. March 09, 2009; Posted: 08:05 AM

Mar 09, 2009 (Datamonitor via COMTEX) -- AEZS | Quote | Chart | News | PowerRating -- Sanofi-Aventis US has signed an agreement with AEterna Zentaris for the development, registration and marketing of cetrorelix pamoate, a luteinizing hormone-releasing hormone antagonist, for the treatment of benign prostatic hyperplasia, in the US.

Cetrorelix pamoate, a long-acting intramuscular injection, is currently in three Phase III trials involving more than 1,600 patients with symptomatic benign prostatic hyperplasia (BPH) in Canada, the US and Europe.

In Phase II studies, cetrorelix pamoate was well-tolerated and provided fast and long-lasting relief of BPH symptoms with a low incidence of sexual side effects, said Sanofi. First efficacy results from the Phase III program are expected during 2009 with potential for new drug application submission in 2010.

AEterna Zentaris will be responsible for completing the Phase III program and regulatory submission in the US. Sanofi-Aventis will be responsible for all commercial activities, including Phase IIIb and Phase IV trials, and will book sales in the US. AEterna Zentaris has retained certain rights to co-promote the product in the US.

Under the terms of the agreement, Sanofi-Aventis will make upfront and future milestone payments and AEterna Zentaris will be eligible for royalties on future product sales.

Brent Ragans, vice president of the general therapeutics business unit at Sanofi-Aventis US, said: "This deal complements our strong presence in the urology space with Uroxatral (alfuzosin), Eligard (leuprolide) and Cialis (tadalafil), co-promoted with Eli Lilly. Cetrorelix is a strategic fit with our urology specialty sales force which is highly experienced in the promotion of products for urologic health."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

For full details on Aeterna Zentaris Inc New (AEZS) click here. Aeterna Zentaris Inc New (AEZS) has Short Term PowerRatings of 4. Details on Aeterna Zentaris Inc New (AEZS) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

Tax Relief Bank Levy Wage Garnishment

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.